Mario Balsa

0

1

27

Stefania Colasanti@Stefani19753108·1d

@MarioBalsaMD 💯🔝👏🙌 @MarioBalsaMD

QME

0

1

73

Mario Balsa@MarioBalsaMD·1d

Does timing matter? Maybe. Does methodology matter? Absolutely! Happy to discuss this elegant SWOG S1404 analysis showing how rigorous statistics can overturn an appealing clinical hypothesis 💥 If you’re interested in melanoma, adjuvant immunotherapy, and why bias matters, I hope you enjoy this week’s #WeekInOncology with @OncoAlert 🧡 @hospitalclinic @myESMO @_SEOM

🕒 Does the time of day of immunotherapy matter? It is NOW time for This #WeekInOncology by @OncoAlert 🚨, this time with our AF colleague @MarioBalsaMD 🇪🇸Discussing the latest in #Melanoma A multicenter analysis of 628 patients with high-risk #melanoma treated with adjuvant #Pembrolizumab found no significant association between infusion timing and recurrence-free or overall survival after accounting for important sources of bias. These findings challenge previous reports suggesting earlier immunotherapy infusions improve outcomes and highlight the importance of rigorous statistical methodology in interpreting timing-related treatment effects. JCO OP Publication👇being discussed: Addressing Biases in Analysis of Time of Infusion: NCI/SWOG🇺🇸 Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti–PD-1 Therapy ascopubs.org/doi/abs/10.120… @EladSharonMD @KenGrossmannMD @jmkirkwood @VernSondakMD @DrSapnaPatel @mihalcioiui Pinging #OncoAlertAF Faculty @nataliagandur @realbowtiedoc @FernandoOnco @ElisaAgostinett @to_be_elizabeth @MarioBalsaMD @BRicciutiMD @HHorinouchi @UOzkerim @p_ciracimd @AmandaNizamMD @scocmem @DrVilmaPBarcia @DraMartinezLago @DrMirallas @GIMedOnc @BettinaRyll @DrBetofMDPhD pinging @FunchainMD @CureMelanoma @Melanoma_doctor @HTawbi_MDPhD @Chrystal_Paulos @JaniceM10 @ProfGLongMIA @ProfRAScolyer @JeffGershenwald @MelanomaAus @AIMatMelanoma

English

5

14

7.8K

Mario Balsa@MarioBalsaMD·1d

@Stefani19753108 @OncoAlert ☺️

QME

1

30

Stefania Colasanti@Stefani19753108·1d

@OncoAlert @MarioBalsaMD 👏👏👏🙌🙌🙌 @MarioBalsaMD

QME

0

2

53

OncoAlert@OncoAlert·1d

🕒 Does the time of day of immunotherapy matter? It is NOW time for This #WeekInOncology by @OncoAlert 🚨, this time with our AF colleague @MarioBalsaMD 🇪🇸Discussing the latest in #Melanoma A multicenter analysis of 628 patients with high-risk #melanoma treated with adjuvant #Pembrolizumab found no significant association between infusion timing and recurrence-free or overall survival after accounting for important sources of bias. These findings challenge previous reports suggesting earlier immunotherapy infusions improve outcomes and highlight the importance of rigorous statistical methodology in interpreting timing-related treatment effects. JCO OP Publication👇being discussed: Addressing Biases in Analysis of Time of Infusion: NCI/SWOG🇺🇸 Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti–PD-1 Therapy ascopubs.org/doi/abs/10.120… @EladSharonMD @KenGrossmannMD @jmkirkwood @VernSondakMD @DrSapnaPatel @mihalcioiui Pinging #OncoAlertAF Faculty @nataliagandur @realbowtiedoc @FernandoOnco @ElisaAgostinett @to_be_elizabeth @MarioBalsaMD @BRicciutiMD @HHorinouchi @UOzkerim @p_ciracimd @AmandaNizamMD @scocmem @DrVilmaPBarcia @DraMartinezLago @DrMirallas @GIMedOnc @BettinaRyll @DrBetofMDPhD pinging @FunchainMD @CureMelanoma @Melanoma_doctor @HTawbi_MDPhD @Chrystal_Paulos @JaniceM10 @ProfGLongMIA @ProfRAScolyer @JeffGershenwald @MelanomaAus @AIMatMelanoma

English

4

16

5.3K

Mario Balsa@MarioBalsaMD·1d

@nataliagandur @OncoAlert Thank you so much Natalia! Really appreciate it 🧡

English

2

47

Dra. María Natalia Gandur Quiroga@nataliagandur·1d

⏰ Does the timing of immunotherapy really matter? This week's #WeekInOncology by @OncoAlert 🚨 features an outstanding review by our AF colleague @MarioBalsaMD 🇪🇸, who breaks down the latest evidence in #Melanoma with his trademark clarity and clinical insight. 📄 Discussing the JCO OP analysis of the NCI/SWOG S1404 trial: A multicenter study of 628 patients receiving adjuvant #Pembrolizumab found no significant association between infusion timing and recurrence-free or overall survival after rigorous adjustment for time-related biases. 💡 An important reminder that robust methodology is just as critical as the clinical question itself—and that not every appealing hypothesis withstands careful analysis. 📖 JCO OP: ascopubs.org/doi/abs/10.120… 👏 Excellent summary by @MarioBalsaMD!! @EladSharonMD @KenGrossmannMD @jmkirkwood @VernSondakMD @DrSapnaPatel @mihalcioiui #WeekInOncology #OncoAlert #Immunotherapy #SkinCancer #ClinicalResearch

🕒 Does the time of day of immunotherapy matter? It is NOW time for This #WeekInOncology by @OncoAlert 🚨, this time with our AF colleague @MarioBalsaMD 🇪🇸Discussing the latest in #Melanoma A multicenter analysis of 628 patients with high-risk #melanoma treated with adjuvant #Pembrolizumab found no significant association between infusion timing and recurrence-free or overall survival after accounting for important sources of bias. These findings challenge previous reports suggesting earlier immunotherapy infusions improve outcomes and highlight the importance of rigorous statistical methodology in interpreting timing-related treatment effects. JCO OP Publication👇being discussed: Addressing Biases in Analysis of Time of Infusion: NCI/SWOG🇺🇸 Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti–PD-1 Therapy ascopubs.org/doi/abs/10.120… @EladSharonMD @KenGrossmannMD @jmkirkwood @VernSondakMD @DrSapnaPatel @mihalcioiui Pinging #OncoAlertAF Faculty @nataliagandur @realbowtiedoc @FernandoOnco @ElisaAgostinett @to_be_elizabeth @MarioBalsaMD @BRicciutiMD @HHorinouchi @UOzkerim @p_ciracimd @AmandaNizamMD @scocmem @DrVilmaPBarcia @DraMartinezLago @DrMirallas @GIMedOnc @BettinaRyll @DrBetofMDPhD pinging @FunchainMD @CureMelanoma @Melanoma_doctor @HTawbi_MDPhD @Chrystal_Paulos @JaniceM10 @ProfGLongMIA @ProfRAScolyer @JeffGershenwald @MelanomaAus @AIMatMelanoma

Caseros, Argentina 🇦🇷 English

3

7

614

Mario Balsa@MarioBalsaMD·1d

@DrVilmaPBarcia @OncoAlert Thank you so much Vilma! 🧡 So happy watching my first scientific video in English…sounding like Sofía Vergara 😂

English

0

5

161

Vilma P. Barcia MD, PhD, MSc@DrVilmaPBarcia·1d

Excellent Mario!!! Super proud🤩🤩 @MarioBalsaMD @OncoAlert

🕒 Does the time of day of immunotherapy matter? It is NOW time for This #WeekInOncology by @OncoAlert 🚨, this time with our AF colleague @MarioBalsaMD 🇪🇸Discussing the latest in #Melanoma A multicenter analysis of 628 patients with high-risk #melanoma treated with adjuvant #Pembrolizumab found no significant association between infusion timing and recurrence-free or overall survival after accounting for important sources of bias. These findings challenge previous reports suggesting earlier immunotherapy infusions improve outcomes and highlight the importance of rigorous statistical methodology in interpreting timing-related treatment effects. JCO OP Publication👇being discussed: Addressing Biases in Analysis of Time of Infusion: NCI/SWOG🇺🇸 Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti–PD-1 Therapy ascopubs.org/doi/abs/10.120… @EladSharonMD @KenGrossmannMD @jmkirkwood @VernSondakMD @DrSapnaPatel @mihalcioiui Pinging #OncoAlertAF Faculty @nataliagandur @realbowtiedoc @FernandoOnco @ElisaAgostinett @to_be_elizabeth @MarioBalsaMD @BRicciutiMD @HHorinouchi @UOzkerim @p_ciracimd @AmandaNizamMD @scocmem @DrVilmaPBarcia @DraMartinezLago @DrMirallas @GIMedOnc @BettinaRyll @DrBetofMDPhD pinging @FunchainMD @CureMelanoma @Melanoma_doctor @HTawbi_MDPhD @Chrystal_Paulos @JaniceM10 @ProfGLongMIA @ProfRAScolyer @JeffGershenwald @MelanomaAus @AIMatMelanoma

Français

2

7

1.5K

Mario Balsa@MarioBalsaMD·1d

🧬 Plasma extracellular vesicle proteome as a predictor of ICI resistance in advanced melanoma (n=46) onlinelibrary.wiley.com/doi/10.1002/ij… ▪️ Baseline EV proteomic signatures distinguished primary, secondary, and overall resistance to IO 💥 Primary resistance: linked to Fcγ receptor signaling || Secondary resistance: distinct complement- and platelet-related EV patterns 🎯 EV-derived biomarker signatures independently predicted PFS @OncoAlert @OncoReporte @myESMO @_SEOM

English

6

18

1.5K

Mario Balsa@MarioBalsaMD·2d

@oncodaily Thank you for sharing!

English

109

OncoDaily@oncodaily·2d

No Association Between Anti–PD-1 Infusion Timing and Survival - Mario Balsa @MarioBalsaMD oncodaily.com/science/mario-…

English

2

5

417

Mario Balsa@MarioBalsaMD·2d

🤔 Long-term survivors after anti–PD-1 in advanced melanoma (n=58)! What about 4-1BB⁺ CD4 T cells? academic.oup.com/jimmunol/artic… ▪️Baseline CD4/CD8 T-cell subsets did not differ by survival 💥 Long-term survivors showed an early increase in 4-1BB⁺ CD4 T cells during treatment 🎯 This was associated with increased LAG3⁺TIM3⁺ CD4 T cells and later reduced FOXP3⁺ CD4 T cells 🩸 On-treatment immune dynamics, rather than baseline, may better identify durable responders @OncoAlert @OncoReporte @myESMO @_SEOM

English

4

7

23

2K

Mario Balsa@MarioBalsaMD·3d

🧬 Nectin-4 as a predictor of immune-related adverse events with adjuvant anti–PD-1 in melanoma (n=43) ovid.com/jnls/melanomar… 💥 Higher baseline Nectin-4 associated with thyroiditis and hepatitis 🔴 Siglec-7/9 associated with any irAE ▪️ Nectin-4 remained significant after FDR correction ☝🏼Exploratory cohort; prospective validation required Nectin-4 may not only help cells stick together…it may help toxicity signals stick out 🔬 @OncoAlert @OncoReporte @myESMO @_SEOM

English

11

18

1.2K

Mario Balsa retweetledi

Katy Beckermann@katy_beckermann·4d

Perioperative EV plus pembrolizumab is now approved for every MIBC patient headed for cystectomy, cisplatin-eligible or not. The FDA expanded the label today on the strength of a head-to-head win over cisplatin-based chemo, the standard we've used for 20 years. 🧪 KEYNOTE-B15/EV-304: 808 cisplatin-eligible patients, perioperative EV + pembro vs neoadjuvant gemcitabine + cisplatin 🎯 EFS: HR 0.53 (median not reached vs 48.5 mo), p<0.0001 📈 OS: HR 0.65, p=0.0029 This is the first time a perioperative regimen has beaten cisplatin-based chemotherapy on survival in eligible MIBC. Reviewed by FDA through Project Orbis, cleared five weeks early. 👉bit.ly/evpembro-mibc @tompowles1 #BladderCancer #MIBC #GUonc

English

19

20

1.6K

Mario Balsa@MarioBalsaMD·4d

🤰 Pregnancy and risk of melanoma: a matched retrospective cohort study (854,193 pregnant vs 854,193 nonpregnant women) ovid.com/jnls/melanomar… 🤔 Pregnancy-associated melanoma has long been debated, with hypotheses that gestational immune tolerance and elevated sex hormones may promote melanocytic transformation 🎯 No increased invasive melanoma risk: HR 0.92 (CI: 0.78–1.07) 🎯 No increased melanoma in situ risk: HR 1.01 (CI: 0.82–1.24) 🔍 Sensitivity analysis remained consistent Gestation may reshape immunity, but here it does not seem to gestate extra melanoma risk 🧬 @OncoAlert @OncoReporte @_SEOM @myESMO

English

7

11

1.3K

Mario Balsa@MarioBalsaMD·4d

Looking forward to this one! From radon to the exposome, understanding how our environment shapes cancer risk is becoming increasingly relevant 🎯 I’m sure @LauraMezquitaMD will deliver another outstanding session. Don’t miss it! 💥 @hospitalclinic @idibaps @ASEICAnews

ASEICA@ASEICAnews

📍No te pierdas el próximo MEET THE EXPERT con @LauraMezquitaMD (@hospitalclinic @idibaps) ✅"From Radon to the Exposome: An Oncologist's Unconventional Path in Cancer Research” ⏰Jueves, 16 de julio (14:00 h) ✍️ form.jotform.com/261674243353356

English

3

7

692

Mario Balsa@MarioBalsaMD·4d

Some trials deserve more than just reading the abstract! That’s exactly what #WeekInOncology is all about💥 @OncoAlert LITESPARK-022 is a perfect example of why expert discussion matters: balancing DFS benefit, toxicity, and the unanswered OS question! Congrats @nataliagandur! Always setting the bar high 🧡

This #WeekInOncology by @OncoAlert| GU Edition 🚨 Today, our GU Faculty Dr. Natalia Gandur 🇦🇷 reviews the LITESPARK-022 trial, led by OncoAlert Faculty member Dr. Toni K. Choueiri.🇺🇸 📄 Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma NEJM, July 1, 2026 LINK👉 buff.ly/OqaCA64 The phase 3 trial showed that adding the HIF-2α inhibitor belzutifan to adjuvant pembrolizumab after nephrectomy significantly improved disease-free survival in high-risk clear-cell RCC. 🔬 Key results: ➡️ DFS benefit: HR 0.72 (95% CI, 0.59–0.87; P<0.001) ➡️ 24-month DFS: 80.7% vs 73.7% ➡️ No significant OS difference at interim analysis ➡️ Higher grade ≥3 toxicities with combination therapy (52.1% vs 30.2%) 🎥 Watch Dr. Gandur’s expert discussion on this important advance in GU oncology. #KidneyCancer #GUOncology #RenalCellCarcinoma #Oncology #Immunotherapy #OncoAlert @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @AlbigesL @cdanicas @amerseburger @sonpavde @DrDanielHeng @declangmurphy @seanmmcbride @HHammersMD @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @scocmem @ravikanesvaran @AmandaNizamMD @drenriquegrande @BraunMDPhD @EfstathiouEleni @nataliagandur @crisbergerot @motzermd @PBarataMD @DrIacovelli

English

5

6

1.3K

Mario Balsa@MarioBalsaMD·4d

⏰ Does the timing of anti–PD-1 infusions matter? (NCI/SWOG S1404, n=628) ascopubs.org/doi/full/10.12… ☝🏼 No association between earlier infusion time and RFS or OS after bias-adjusted analyses 💥 Time-dependent multivariable models failed to confirm any survival benefit 🚗 Distance to the treatment center influenced infusion timing, highlighting an important confounder Maybe the clock wasn’t ticking in favor of IO…just in favor of bias! @OncoAlert @OncoReporte @_SEOM @myESMO

English

18

42

24.2K

Mario Balsa@MarioBalsaMD·4d

📄 Surgical feasibility and outcomes following neoadjuvant ICI before surgery in resectable stage III/IV melanoma (Systematic review & meta-analysis, 20 studies, n=1,384) link.springer.com/article/10.124… 🎯 pCR 33% | MPR 46% | Overall pathological response 59% 🔴 Failure/delay to surgery: 9% ⚠️ Major surgical complications: 8% 💥 Lower recurrence risk vs adjuvant approaches @OncoAlert @OncoReporte @myESMO @_SEOM

English

Margarita@Margari05945666

7

9

826

Mario Balsa@MarioBalsaMD·4d

Qué peligro hablar con tanta rotundidad sobre algo que es objetivamente falso. Los diagnósticos de cáncer se confirman con anatomía patológica y la quimioterapia sin diagnóstico histológico es una excepción extraordinaria, no la norma. El cáncer ya da suficiente miedo como para añadir bulos. Qué poca vergüenza dar voz a opiniones libres de hechos @La_SER @laventana

Hermanos Barea, [9 de jul de 2026 a las 14:18] “Hay un 40% de falsos positivos en diagnósticos de cáncer”. Los pasan por la quimioterapia sin tener cáncer y eso es casi una de cada dos personas.

Español

4

11

1.2K

Mario Balsa@MarioBalsaMD·4d

@DraMartinezLago @OncoAlert @myESMO @GrupoTTD @ASCO Congrats @DraMartinezLago!! 👏🏼

English

1

112

Nieves Martinez Lago MD PhD@DraMartinezLago·5d

Proud to share that the RAS wild-type subanalysis of the BeTAS study has been accepted as an e-Poster at #ESMO26! 🎉 Thank you to the 19 participating Spanish centres. This achievement belongs to all of us. 🇪🇸 @OncoAlert

English

3

26

1.5K

Mario Balsa@MarioBalsaMD·5d

@ivanpantic1980 @YGaritaonaindia @GrupoMelanoma Completely agree! Clinical trials should always come first whenever feasible!

English

1

49

Iván Márquez Rodas 🇪🇦@ivanpantic1980·5d

@MarioBalsaMD Thank you very much for your comments! Yes, this study confirms that in this situation we must try to look for clinical trial alternatives and chemo should be reserved for very selected cases with no alternatives available. @GrupoMelanoma

English

2

177

Mario Balsa@MarioBalsaMD·5d

🤔 ChT after IO in advanced melanoma (GEM1801 real-world study, Spain 🇪🇸) acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… 👥 92 patients treated with ChT after prior IO 🎯 ORR 12% ⏳ mPFS 3.5 months | mOS 6.1 months ▪️Outcomes remained poor regardless of the ChT regimen used ChT still has a place…it just seems to be at the end of the line🚉 Congrats to all the investigators! @GrupoMelanoma @ivanpantic1980 @DraT_Puertolas @OncoAlert @OncoReporte @myESMO @_SEOM

English

14

16

843

Mario Balsa@MarioBalsaMD·5d

🚨 Every week, the oncology literature grows. So does the need for trusted expert curation! Another outstanding edition of the @OncoAlert Newsletter covering the science that matters most 🔗 oncoalert.m-pages.com/nhMpwe/oncoale…

📢 The OncoAlert Newsletter | This Week's Edition Is Out 🔥July 2-9 REGISTER TO GET IT👉 buff.ly/X6N7qLU or buff.ly/4xd4naf ⭐ SPOTLIGHT TRIAL: Adjuvant Pembrolizumab + Belzutifan for Renal-Cell Carcinoma — does adding a HIF-2α inhibitor to adjuvant immunotherapy change the game for high-risk resected ccRCC? The phase 3 data are in, and the efficacy-toxicity trade-off is worth a close look. Also in this edition: 🧬 Casdatifan's durable HIF-2α-driven response in refractory metastatic RCC 🩺 APCCC 2025: consensus reached on just 19% of prostate cancer diagnostic questions 🫁 Do PPIs blunt durvalumab's efficacy after chemoradiotherapy in stage III NSCLC? 🎯 [177Lu]Lu-edotreotide outperforming everolimus in GEP-NETs (COMPETE trial) 🎗️ Trastuzumab rezetecan nearly quadruples PFS in HER2+ metastatic breast cancer ➕ 4 more studies spanning lung, GI, breast, gyn onc, and multiple myeloma Curated for oncology professionals, by oncology professionals. Read the full edition 👉 OncoAlert360.com #OncologyNews #RenalCellCarcinoma #KidneyCancer #NSCLC #BreastCancer #NeuroendocrineTumors #MultipleMyeloma #Oncology #ClinicalResearch #OncoAlert @OncoAlert @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @JaniceTNBCmets @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @sonpavde @drenriquegrande @tompowles1 @cdanicas @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem @FernandoOnco @ElisaAgostinett @to_be_elizabeth @Erman_Akkus @MarioBalsaMD @DrMirallas @GIMedOnc @UOzkerim @DrRishabhOnco @PaulJiL @DaisukeKotani @DraMartinezLago @p_ciracimd @BenWestphalen @CentralParkWMD @graokane @amandaNizamMD @DrVilmaPBarcia

English